发明名称 Use of NK-1 receptor antagonists in pruritus
摘要 The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
申请公布号 US9381188(B2) 申请公布日期 2016.07.05
申请号 US201514922684 申请日期 2015.10.26
申请人 TIGERCAT PHARMA, INC. 发明人 Zhang Xiaoming;Schnipper Edward F.;Perlman Andrew J.;Larrick James W.
分类号 A61K31/403;A61K45/06;A61K9/00;A61K31/4035;A61K47/10;A61K9/06;A61K9/20;A61K9/48 主分类号 A61K31/403
代理机构 The Marbury Law Group PLLC 代理人 The Marbury Law Group PLLC
主权项 1. A method of treating pruritus, comprising administering a therapeutically effective amount of 3-[(3aR,4R,5S,7aS)-5-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-4-(4-fluorophenyl)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]cyclopent-2-en-1-one (serlopitant) or a pharmaceutically acceptable salt, solvate or polymorph thereof to a patient in need of treatment.
地址 South San Francisco CA US